NK - ネクタ―・セラピュ―ティクス (NantKwest Inc.)

NKのニュース

   NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested  2020/06/10 13:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the publication of two peer-reviewed manuscripts in the Journal of Immunotherapy of Cancer. These invitro and in-vivo studies, conducted in collaboration with the National Cancer Institute pursuant to a Cooperative Research and Development Agreement, support the mechanism and functionality of NantKwest’s clinical-stage engineered natural killer (NK
   The race for coronavirus treatments and vaccines is heating up. Here are the 12 most important events to watch for in June, from fresh vaccine data to new antibody drug trials.  2020/06/01 12:25:00 Business Insider
The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to watch for this month, including new drugs and vaccines starting human testing and a range of data readouts from ongoing studies. The catalysts will impact drug companies ranging in size from massive to tiny, including biopharma giants like Eli Lilly and Regeneron and small biotechs like NantKwest and Inovio Pharmaceuticals. Visit Business Insider's homepage for more stories . June is shaping up to be a critical month for several coronavirus treatment and vaccine research programs. Some will start human testing for the first time, while others will wrap up and report results from clinical trials. There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people.
   NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates  2020/05/27 17:56:10 Benzinga
Nantkwest Inc (NASDAQ: NK ) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options. Vaccine Program Part Of ‘Operation Warp Speed' El Segundo, California-based NantKwest said its affiliate ImmunityBio has been selected to participate in Operation Warp Speed , a national program aimed at providing substantial quantities of safe, effective vaccine for Americans by January 2021. NanKwest said it will focus on developing, testing and largescale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate, codenamed hAd5. The company said it's the first vaccine designed to deliver both Spike and Nucleocapsid DNA, offering scope for long-lasting immunity. "ImmunityBio is honored to have been selected as one of the 14 companies for Operation Warp Speed and is committed to moving our … Full story available on Benzinga.com
   ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine  2020/05/27 16:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-
   NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 13:30:00 Business Wire
EL SEGUNDO, Calif.,--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days. About NantKwe
   The race for coronavirus treatments and vaccines is heating up. Here are the 12 most important events to watch for in June, from fresh vaccine data to new antibody drug trials.  2020/06/01 12:25:00 Business Insider
The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to watch for this month, including new drugs and vaccines starting human testing and a range of data readouts from ongoing studies. The catalysts will impact drug companies ranging in size from massive to tiny, including biopharma giants like Eli Lilly and Regeneron and small biotechs like NantKwest and Inovio Pharmaceuticals. Visit Business Insider's homepage for more stories . June is shaping up to be a critical month for several coronavirus treatment and vaccine research programs. Some will start human testing for the first time, while others will wrap up and report results from clinical trials. There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people.
   NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates  2020/05/27 17:56:10 Benzinga
Nantkwest Inc (NASDAQ: NK ) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options. Vaccine Program Part Of ‘Operation Warp Speed' El Segundo, California-based NantKwest said its affiliate ImmunityBio has been selected to participate in Operation Warp Speed , a national program aimed at providing substantial quantities of safe, effective vaccine for Americans by January 2021. NanKwest said it will focus on developing, testing and largescale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate, codenamed hAd5. The company said it's the first vaccine designed to deliver both Spike and Nucleocapsid DNA, offering scope for long-lasting immunity. "ImmunityBio is honored to have been selected as one of the 14 companies for Operation Warp Speed and is committed to moving our … Full story available on Benzinga.com
   ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine  2020/05/27 16:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-
   NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 13:30:00 Business Wire
EL SEGUNDO, Calif.,--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days. About NantKwe
   Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths  2020/05/19 12:00:00 Business Wire
MINNEAPOLIS & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b trial to address one of the primary causes of COVID-19 deaths.
   NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients  2020/05/18 12:30:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide dono
   Talc Miner Imerys to Forfeit North America Units to Settle 14,000 Cancer Lawsuits  2020/05/18 05:00:47 Insurance Journal
Imerys SA, which mines talc used in Johnson & Johnson’s iconic Baby Powder and other products, agreed to turn over its North American operations to resolve more than 14,000 lawsuits claiming the mineral caused cancer in some consumers. Imerys Talc …
   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
   NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer  2020/05/14 20:25:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy: NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of lo
   NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference  2020/04/29 20:15:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET. A live audio webcast of the conference presentation will be available on the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for app

calendar